Our study demonstrated that while manipulating intra-tumoral or systemic TNF levels is practically challenging, the anti-tumor effect of TNF can still be harnessed by selectively targeting its downstream signaling kinases including TAK1 and MK2 in order to improve treatment efficacy (Grierson et al., Science Translational Medicine, in press). This evidence concerns the gene MAP3K7 and neoplasm.